Age-related Macular Degeneration Market Updates

Age-related Macular Degeneration Market size was valued at USD 10.19 Billion in 2023 and is poised to grow from USD 11.29 Billion in 2024 to USD 25.66 Billion by 2032, growing at a CAGR of 10.80% during the forecast period (2025-2032).

The competitive global age-related macular degeneration market denotes that a host of various pharmaceutical companies struggle to capture market share with their new therapies. Novartis’ Lucentis is one of the key anti-VEGF drugs while Eylea, developed by Regeneron Pharmaceuticals, stands out. To mention but a few Roche’s Avastin is part of key players in this field. They work hard developing advanced treatment modalities meant at ensuring better patient outcomes and filling any existing gap in terms of successful therapies. Thereby competition enhances ongoing innovations, which consequently leads to more effective treatments being available for AMD patients globally. 'Biogen  ', 'Formycon AG ', 'Coherus Biosciences ', 'Biocon  ', 'Outlook Therapeutics, Inc.  ', 'Teva Pharmaceutical Industries Ltd.  ', 'Intas Pharmaceuticals Ltd.  ', 'Chengdu Kanghong Pharmaceutical Group Co., Ltd.  ', 'Ocular Therapeutix, Inc.  ', 'Opthea Limited  ', 'Kodiak Sciences Inc.  ', 'Bio-Thera  ', 'Amgen Inc.  ', 'Alvotech  ', 'Stealth Biotherapeutics Inc.  ', 'Alteogen Inc.  ', 'Ocumension Therapeutics ', 'Innovent  ', 'Regeneron Pharmaceuticals, Inc.  ', 'Shanghai Henlius Biotech, Inc. '

Increased elderly population being susceptible to AMD is driving the global age-related macular degeneration market. The longer people live, the more they are exposed to its risk which leads in turn to requests for AMD therapies and treatments so as to manage and stop sight loss.

Emergence of Long-Acting Therapies: In the AMD market there is an increasing trend towards long-action therapies like anti-VEGF treatments of extended duration. These innovations help in reducing the number of times patients need to be injected, hence improving their compliance and results; thus, fueling growth within the market that has had its challenges with earlier treatments.

North America is ahead in the global age-related macular degeneration market as its healthcare system is advanced, it has a high prevalence rate of AMD and there are significant investments in research. In addition, the region enjoys established regulatory pathways which enable faster access to innovative treatments. Moreover, there are strong awareness programs and high health care expenditures that support the wide use of advanced therapies. The presence of leading pharmaceutical companies and clinical trial hubs in North America further supports its dominance. The growing aging population and increasing incidence of AMD in this region drive continuous demand for effective treatment solutions, reinforcing North America's market leadership.